EKSO
Ekso Bionics Holdings, Inc.4.7000
+0.0500+1.08%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
12.33MP/E (TTM)
-Basic EPS (TTM)
-5.38Dividend Yield
0%Recent Filings
10-K
FY2025 results
Ekso Bionics delivered FY2025 revenue of $12.8M, down 29% y/y, as Enterprise Health device sales in EMEA dropped sharply while Personal Health sales in the Americas rose on CMS reimbursement progress for Ekso Indego Personal, building a backlog of over 50 qualified prospects. Gross margins held steady at 53%, but operating expenses edged up 1% to $20.2M amid impairments on trade name ($0.6M) and IP ($0.2M) assets, driving a $13.3M operating loss (up 27% y/y) and $11.7M net loss. Cash dwindled to $1.2M by year-end amid $11.8M operating burn, offset by $6.6M in financings; debt includes $2.4M B. Riley note (due Sep 2026) and $2.2M Parker note (due 2027). No 2026 guidance disclosed. Reimbursement delays from CMS could stall Personal Health momentum.
8-K
Ekso acquires Cloud, APLD takes 97%
Ekso Bionics signed a Contribution and Exchange Agreement on February 15, 2026, to acquire Applied Digital Cloud Corporation in exchange for 138,216,820 new shares, handing APLD 97% ownership of the renamed ChronoScale while Ekso legacy holders retain 3%. Closing, targeted for Q2 2026, hinges on stockholder approval, $15M cash (including PIPE), and Nasdaq listing. Q4 2025 revenue plunged to $3.0-3.1M from $5.1M; cash dwindled to $1.2M.
8-K
Ekso raises $5.3M via preferred
Ekso Bionics closed a private placement on January 22, 2026, issuing 5,852 shares of Series B Convertible Preferred Stock (stated value $1,000/share, convertible into 711,922 common shares at $8.22) and warrants for 355,960 common shares at $8.22 to institutional investors. Net proceeds approximate $5.3 million for working capital and general corporate purposes. Purchasers face a six-month transfer lockup, barring short sales.
8-K
Ekso proposes AI cloud merger
Ekso Bionics signed a non-binding term sheet on December 29, 2025, to combine with Applied Digital's cloud business, forming ChronoScale—an AI-focused compute platform where Applied owns ~97% and Ekso shareholders ~3%. Ekso's exoskeleton operations continue while pursuing a sale. Deal targets H1 2026 close, but hinges on due diligence and approvals. Risks loom large.
8-K
Execs get RSUs, CIC severance
Ekso Bionics granted RSUs and Phantom PSUs to executives Scott Davis, Jerome Wong, and Jason Jones on November 5, 2025, to boost retention and align with stockholder growth. RSUs fully vested immediately; Phantom PSUs vest on Change in Control plus $7.50 stock price within five years, settling in cash. New severance deals supersede priors, offering 6-9 months pay outside CIC, doubling for Davis in CIC with equity acceleration. Retention locked in, but hinges on M&A.
IPO
Website
Employees
Sector
Industry
BSX
Boston Scientific Corporation
92.95+0.76
CTSO
Cytosorbents Corporation
0.64+0.01
DHAI
DIH Holding US, Inc.
0.75+0.16
DYNT
Dynatronics Corp.
0.04+0.00
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
LFWD
Lifeward Ltd.
0.64+0.02
MYO
Myomo Inc.
1.04+0.04
OSSFF
EMBLA MEDICAL
5.33+0.00
PLSE
Pulse Biosciences, Inc
14.23+0.10
RBOT
Vicarious Surgical Inc.
2.43-0.04